Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Lymphoid 1Genitourinary 1

Conditions

Ovarian Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Lymphoma, Follicular 1Lymphoma 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Has results × FANG vaccine × Clear all
NCT01309230 2025-06-08

A Trial of FANGâ„¢ Vaccine for Participants With Ovarian Cancer

Gradalis, Inc.

Phase 2 Completed
39 enrolled 13 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00006478 2023-09-18

Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma

University of Nebraska

Phase 2 Terminated
19 enrolled 4 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT03073525 2023-04-05

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Gradalis, Inc.

Phase 2 Completed
25 enrolled 15 charts
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms

NCT02511132 2022-12-22

A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Gradalis, Inc.

Phase 2 Completed
22 enrolled 13 charts
Sarcoma

Sarcoma, Sarcoma, Ewing

NCT00085436 2018-06-26

DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

Dartmouth-Hitchcock Medical Center

Phase 2 Completed
18 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡